Background

Duchenne Muscular Dystrophy (DMD) is caused by a genetic defect in the dystrophin protein gene, which is essential for maintaining muscle integrity. The progressive destruction of muscle cell membranes leads to a debilitating genetic disorder characterized by weakening of muscles throughout the body. Patients typically begin experiencing gait disturbances at a young age, eventually succumbing to respiratory and cardiac muscle failure. Cardiac muscle dysfunction, in particular, has been identified as a critical factor determining patient survival. Due to the lack of definitive treatments, management has been limited to supportive care aimed at alleviating symptoms.

Recent advances in gene therapy have emerged as a promising alternative, focusing on compensating for damaged genes. This approach involves delivering a microdystrophin gene, which contains only the key functional regions of the dystrophin gene, into cells using an adeno-associated virus (AAV) vector. Delandistrogene Moxeparvovec (Elevidys), a representative drug, has generated significant expectations for its potential to restore muscle function in patients. However, the specific effects of gene therapy on cardiac tissue and clinical data on in vivo protein expression efficiency remain limited.

Key Findings

A research team led by Dr. Benjamin J. Samelson-Jones at the Children’s Hospital of Philadelphia (CHOP) meticulously tracked cardiac adverse events in a patient who received Elevidys, and the results have garnered attention. The study revealed that the patient exhibited signs of rapid cardiac function deterioration approximately 42 days after gene therapy administration. The medical team promptly initiated high-dose intravenous steroid treatment to mitigate myocardial damage. Furthermore, they implemented more intensive cardiac monitoring than the product label's recommended guidelines.

To elucidate the biological mechanisms underlying the adverse effects observed after treatment, the research team collected cardiac and biceps muscle tissues from the patient for molecular biological analysis. The analysis confirmed that the expression levels of microdystrophin, the target protein, in both cardiac and skeletal muscle tissues were less than 1% of normal dystrophin levels. This indicates that the therapeutic gene was not adequately delivered into target cells or was not efficiently translated into protein. Furthermore, the limited amount of protein expressed exhibited a heterogeneous distribution, with patchy clusters rather than uniform distribution throughout the muscle cells. The fact that significant cardiac toxicity occurred despite such minimal gene delivery efficiency represents an unusual phenomenon that challenges conventional clinical understanding.

Significance and Prospects

Although this is a case report involving a single patient, it transparently demonstrates the uncertainties regarding the safety and efficacy of high-cost gene therapies. The observation that the heart was damaged despite inadequate microdystrophin production suggests that the immune response or cellular toxicity induced by the viral vector itself may have been a contributing factor. This highlights the potential for adverse effects to outweigh the therapeutic benefits.

In the future, clinicians performing gene therapy should implement more detailed cardiac function monitoring protocols that go beyond the standard guidelines outlined in the existing product labels. Heterogeneous and sparse protein expression can disrupt the cardiac conduction system, posing a risk of potentially fatal arrhythmias. The biotechnology industry also faces significant challenges. Research is needed to develop next-generation vector designs that enhance AAV delivery efficiency while minimizing immunogenicity, and to optimize the dosage regimen.